TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer)(TIGIT/3106), CF640R conjugate, 0.1mg/mL

Primary

Antibodies

CF640R

Store at 2 to 8°C|Protect fluorescent conjugates from light

TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4 T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is a immuno-oncology target for therapy. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Protect from light

Stable at room temperature or 37°C (98°F) for 7 days.

Primary and secondary antibodies for multiple methodology
immunostaining detection application

0.1 mg/mL

Guaranteed for at least 24 months from date of receipt when stored as recommended

Monoclonal

TIGIT

Tonsil or Prostate Carcinoma.

Monospecific